tiprankstipranks
Trending News
More News >
Pfizer (PFE)
NYSE:PFE
Advertisement

Pfizer (PFE) AI Stock Analysis

Compare
35,139 Followers

Top Page

PFE

Pfizer

(NYSE:PFE)

Select Model
Select Model
Select Model
Outperform 83 (OpenAI - 4o)
Rating:83Outperform
Price Target:
$30.00
▲(16.82% Upside)
Pfizer's overall stock score is driven by strong financial performance and positive earnings call sentiment. The company's attractive valuation and high dividend yield further enhance its appeal. Technical analysis presents mixed signals, but the overall outlook remains positive due to strategic initiatives and robust financial health.
Positive Factors
R&D Advancements
Pfizer's strong R&D pipeline, including advancements in multiple myeloma and lung cancer treatments, positions it for long-term growth and market leadership in innovative therapies.
Strategic Business Development
Strategic partnerships, like the agreement with 3SBio, enhance Pfizer's product offerings and market reach, supporting sustained revenue growth and competitive positioning.
Cost Management
Effective cost management improves operating margins, allowing Pfizer to reinvest in growth initiatives and maintain financial health, crucial for long-term competitiveness.
Negative Factors
Pricing Pressures
Pricing pressures from regulatory changes could impact Pfizer's revenue streams, challenging its ability to maintain profit margins and necessitating strategic adjustments.
Competitive Pressures in Oncology
Intense competition in the oncology sector may hinder Pfizer's growth in this high-margin area, affecting its market share and necessitating innovation to stay ahead.
Debt Levels
Rising debt levels could strain Pfizer's financial flexibility, impacting its ability to invest in R&D and strategic initiatives, which are vital for long-term growth.

Pfizer (PFE) vs. SPDR S&P 500 ETF (SPY)

Pfizer Business Overview & Revenue Model

Company DescriptionPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
How the Company Makes MoneyPfizer generates revenue primarily through the sale of prescription medicines and vaccines. The company's revenue model is largely driven by its extensive portfolio of patented drugs, which allows it to charge premium prices. Key revenue streams include sales from its innovative therapies, as well as established brands that continue to perform well in the market. Pfizer also earns revenue from collaborations and partnerships, such as its alliance with BioNTech for the development of the COVID-19 vaccine, which significantly boosted its earnings. Additionally, Pfizer benefits from licensing agreements and royalties associated with its research and development efforts. The company's ability to navigate patent expirations and introduce new products is critical for sustaining its revenue growth.

Pfizer Key Performance Indicators (KPIs)

Any
Any
Global Biopharmaceuticals Revenue by Type
Global Biopharmaceuticals Revenue by Type
Chart Insights
Data provided by:Main Street Data

Pfizer Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment overall, with Pfizer showing strong financial performance, significant advancements in its R&D pipeline, and effective cost management. However, there are some challenges, particularly related to pricing pressures from the IRA Medicare Part D redesign and competitive pressures in the oncology sector.
Q2-2025 Updates
Positive Updates
Strong Year-to-Date Performance and Raised EPS Guidance
Pfizer raised its adjusted diluted EPS guidance for the full year 2025 due to strong year-to-date performance, indicating confidence in its financial outlook.
Significant R&D Advancements
Pfizer highlighted several promising developments in its R&D pipeline, including Elrexfio's notable performance in multiple myeloma and Sigvotatug Vedotin's potential in non-small cell lung cancer.
Strong Growth in Key Products
The Vyndaqel family saw a 21% year-over-year operational growth, and Padcev experienced a 38% operational growth, demonstrating robust demand for key products.
Cost Management and Operating Margins
Pfizer's cost optimization strategies led to an 8% decline in total adjusted operating expenses, contributing to improved operating margins.
Strategic Business Development Initiatives
Pfizer closed an in-licensing agreement with 3SBio, granting exclusive rights to develop and commercialize a promising bispecific antibody.
Negative Updates
Impact of IRA and 340B on Revenue
The IRA Medicare Part D redesign and the 340B program exerted pressure on net revenues, particularly affecting products like Nurtec.
Challenges in Oncology Sector
Seagen products, including ADCETRIS and TUKYSA, faced increased competitive pressures leading to muted growth in certain segments.
Company Guidance
During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and updates on its performance and future guidance. CEO Albert Bourla highlighted Pfizer's strong performance, noting a 10% operational revenue increase to $14.7 billion and raising the adjusted diluted EPS guidance for the full year 2025. The company is actively engaging with policymakers to navigate geopolitical challenges while focusing on R&D productivity, commercial portfolio maximization, and expanding margins. Notable achievements include the progress of Elrexfio in multiple myeloma, with a median overall survival of over two years, and the potential of Sigvotatug Vedotin in non-small cell lung cancer, expected to impact a market projected to reach over $60 billion by 2030. CFO David Denton emphasized strategic financial management, reporting an adjusted EPS of $0.78 and highlighting cost management initiatives contributing to robust operating margins. Pfizer is also preparing for a Phase III start for its C. difficile vaccine candidate and advancing a Phase III program for a Lyme disease vaccine. The company continues to invest in its business, focusing on R&D and strategic partnerships, with a current business development capacity of approximately $13 billion. Overall, Pfizer remains committed to creating long-term shareholder value through disciplined execution and strategic investments.

Pfizer Financial Statement Overview

Summary
Pfizer demonstrates strong financial health with solid profitability and cash generation. The income statement shows a healthy gross profit margin and positive revenue growth. The balance sheet is stable with manageable leverage, though increasing debt poses some risk. Cash flow is robust, enhancing financial flexibility.
Income Statement
85
Very Positive
Pfizer's income statement shows strong profitability with a gross profit margin of 74.09% and a net profit margin of 16.83% for the TTM period. Revenue growth is positive at 2.19%, indicating a recovery from previous declines. The EBIT and EBITDA margins are healthy at 15.14% and 27.78%, respectively, reflecting efficient operations. However, the decline in EBIT margin from the previous year suggests some pressure on operational efficiency.
Balance Sheet
78
Positive
The balance sheet is solid with a debt-to-equity ratio of 0.70, indicating a manageable level of leverage. Return on equity is 11.95%, showing decent profitability relative to shareholder equity. The equity ratio stands at 43.03%, suggesting a strong equity base. However, the increase in total debt over the years could pose a risk if not managed carefully.
Cash Flow
82
Very Positive
Pfizer's cash flow statement is robust, with a free cash flow growth rate of 10.86% in the TTM period. The operating cash flow to net income ratio is 0.40, and the free cash flow to net income ratio is 0.82, indicating strong cash generation relative to earnings. The company has improved its free cash flow position significantly, enhancing financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue63.83B63.63B59.55B100.33B81.29B41.65B
Gross Profit42.99B41.85B30.34B62.09B46.88B29.88B
EBITDA22.77B18.13B9.56B41.03B30.79B13.17B
Net Income10.75B8.02B2.13B31.36B22.15B9.16B
Balance Sheet
Total Assets206.09B213.40B226.50B197.21B181.48B154.23B
Cash, Cash Equivalents and Short-Term Investments13.25B20.48B12.69B22.73B31.07B12.22B
Total Debt61.80B63.65B70.84B34.86B37.00B38.27B
Total Liabilities117.08B124.90B137.21B101.29B104.01B90.76B
Stockholders Equity88.69B88.20B89.01B95.66B77.20B63.24B
Cash Flow
Free Cash Flow12.44B9.84B4.79B26.03B29.87B11.61B
Operating Cash Flow15.19B12.74B8.70B29.27B32.58B14.40B
Investing Cash Flow3.54B2.65B-32.28B-15.78B-22.55B-4.27B
Financing Cash Flow-18.17B-17.14B26.07B-14.83B-9.82B-9.65B

Pfizer Technical Analysis

Technical Analysis Sentiment
Positive
Last Price25.68
Price Trends
50DMA
24.78
Positive
100DMA
24.33
Positive
200DMA
24.26
Positive
Market Momentum
MACD
0.50
Negative
RSI
54.66
Neutral
STOCH
61.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Positive. The current price of 25.68 is above the 20-day moving average (MA) of 24.89, above the 50-day MA of 24.78, and above the 200-day MA of 24.26, indicating a bullish trend. The MACD of 0.50 indicates Negative momentum. The RSI at 54.66 is Neutral, neither overbought nor oversold. The STOCH value of 61.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PFE.

Pfizer Risk Analysis

Pfizer disclosed 26 risk factors in its most recent earnings report. Pfizer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pfizer Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
$150.27B14.0612.16%6.66%14.72%
80
Outperform
$453.15B20.1230.21%2.68%4.69%34.88%
78
Outperform
$251.63B19.0232.82%3.02%12.38%-12.67%
76
Outperform
$221.80B13.6935.44%3.75%2.00%20.01%
70
Outperform
$158.34B24.0699.14%3.19%13.10%110.67%
68
Neutral
$406.64B109.55112.90%2.80%6.05%-29.75%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PFE
Pfizer
25.68
-1.74
-6.35%
AMGN
Amgen
294.62
-16.00
-5.15%
JNJ
Johnson & Johnson
189.69
34.21
22.00%
MRK
Merck & Company
86.40
-19.09
-18.10%
NVS
Novartis
132.31
20.88
18.74%
ABBV
AbbVie
231.24
43.60
23.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 01, 2025